SERB
Location
ILE DE FRANCE
Founded
1951-07-25
Website
Risk Signals
32 news mentions monitored
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Pharmaceutical Preparations), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about SERB
Live alerts from global media, monitored by Business Radar
2025-01-09 (fiercepharma.com)
Catalyst settles with Teva, staving off Firdapse generic until 2035 |
Despite weathering significant criticism from lawmakers and patient groups over the steep cost of its rare disease med Firdapse, Catalyst Pharmaceutical has repeatedly emerged triumphant over its d | Thanks to a new settlement with Catalyst, Teva is barred from marketing its Firdapse generic in the U.S. until Feb. 25, 2035, at the earliest.
Read more
2025-01-08 (globenewswire.com)
Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Teva Pharmaceuticals
As Part of the Settlement, Teva Receives a License to Market Generic FIRDAPSE Beginning in February 2035...
Read more
(endpts.com)
Exclusive: After winning legal battle, former PhaseBio investor finds US buyer for its PhIII drug to reverse Brilinta
Having wrangled control of a blood thinner reversal agent, SFJ Pharma has found a buyer for the drug. SERB Pharmaceuticals, a specialty pharma that vastly expanded its portfolio through several ...
Read more